MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, AVBP had -$93K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$93K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-34,978 -95,786
Stock-based compensation expense
3,716 5,582
Prepaid expenses and other current assets
6,490 6,346
Accounts payable
1,869 280
Accrued expenses
91 2,148
Operating lease liabilities
-6 -10
Net cash used in operating activities
-35,798 -94,132
Purchase of short-term and long-term investments
90,369 31,385
Maturity of short-term and long-term investments
39,609 82,116
Net cash used in investing activities
-50,760 50,731
Proceeds from issuance of common stock, net of issuance costs
167,973 -
Proceeds from the exercise of stock options
49 369
Payment of deferred financing costs
-300 353
Proceeds from issuance of common stock in an initial public offering and atm facility, net of issuance costs
-81,857
Net cash provided by financing activities
86,465 81,873
Net increase in cash and cash equivalents
-93 38,472
Cash and cash equivalents at beginning of period
74,293 -
Cash and cash equivalents at end of period
112,672 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

ArriVent BioPharma, Inc. (AVBP)

ArriVent BioPharma, Inc. (AVBP)